Research graph
References from Eight‐year changes in hepatic steatosis and associated metabolic factors in a Japanese cohort of people with HIV. Local targets link to admitted publications; unresolved targets remain external evidence.
Metabolic dysfunction‐associated steatotic liver disease
10.1056/nejmra2412865 · 2025 · External reference
EASL‐EASD‐EASO clinical practice guidelines on the management of metabolic dysfunction‐associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · 2024 · External reference
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
10.1097/hep.0000000000000323 · 2023 · External reference
Prevalence and risk factors of nonalcoholic fatty liver disease in HIV‐monoinfection
10.1097/qad.0000000000001504 · 2017 · External reference
Pathogenesis of HIV‐associated metabolic syndrome and clinical management recommendations
10.2147/ijgm.s528870 · 2025 · External reference
Prevalence and characteristics of nonalcoholic fatty liver disease and fibrosis in people living with HIV monoinfection: a systematic review and meta‐analysis
10.1016/j.cgh.2023.01.001 · 2023 · External reference
Nonalcoholic fatty liver disease in HIV‐infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors
10.1086/589294 · 2008 · External reference
Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV‐infected patients
10.1097/qad.0000000000000248 · 2014 · External reference
Individual patient data meta‐analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
10.1016/j.jhep.2016.12.022 · 2017 · External reference
Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease
10.1053/j.gastro.2019.01.042 · 2019 · External reference
Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy
10.1016/j.eclinm.2021.101116 · 2021 · External reference
Global prevalence, incidence, and outcomes of non‐obese or lean non‐alcoholic fatty liver disease: a systematic review and meta‐analysis
10.1016/s2468-1253(20)30077-7 · 2020 · External reference
Appropriate body‐mass index for Asian populations and its implications for policy and intervention strategies
10.1016/s0140-6736(03)15268-3 · 2004 · External reference
Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes
10.1016/j.ultrasmedbio.2010.07.005 · 2010 · External reference
Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease
10.1002/hep.23312 · 2010 · External reference
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection
10.1002/hep.21178 · 2006 · External reference
FibroScan‐AST (FAST) score for the non‐invasive identification of patients with non‐alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study
10.1016/s2468-1253(19)30383-8 · 2020 · External reference
A solution to the problem of separation in logistic regression
10.1002/sim.1047 · 2002 · External reference
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large‐scale multicenter retrospective study
10.1111/hepr.13947 · 2023 · External reference
The epidemiology of NAFLD and lean NAFLD in Japan: a meta‐analysis with individual and forecasting analysis, 1995–2040
10.1007/s12072-021-10143-4 · 2021 · External reference
Relationship between drinking frequency and fatty liver prevalence or incidence in Japanese undergoing health checkup in 2008–2019
10.1111/liv.15055 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Risk factors of metabolic dysfunction‐associated fatty liver disease in people with HIV receiving antiretroviral therapy
10.1097/qad.0000000000004419 · 2026 · External reference
Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials
10.1093/cid/ciz999 · 2020 · External reference
Dolutegravir plus two different prodrugs of tenofovir to treat HIV
10.1056/nejmoa1902824 · 2019 · External reference
Weight gain before and after switch from TDF to TAF in a U.S. cohort study
10.1002/jia2.25702 · 2021 · External reference
Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV
10.1016/j.jiac.2022.10.014 · 2023 · External reference
Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV
2024 · External reference
Liver fibrosis, but no other histologic features, is associated with long‐term outcomes of patients with nonalcoholic fatty liver disease
10.1053/j.gastro.2015.04.043 · 2015 · External reference
Metabolic dysfunction‐associated liver disease predicts incident liver fibrosis in people with HIV mono‐infection: a cohort study
10.1111/hiv.70079 · 2025 · External reference
